The American College of Physicians' oral medication guideline for treating type 2 diabetes is the first update since 2012, and it reflects many new medications that have received FDA approval since that time.
The American College of Physicians (ACP) on Tuesday updated its oral medication guidelines for treating type 2 diabetes (T2D), with a specific tip for patients: ask what you will pay for your medication.
ACP published its new guideline, last updated in 2012, in the Annals of Internal Medicine. The journal published a separate summary for patients that features questions to ask physicians, including: “How much will the oral medicines cost?”
The guideline calls for starting with metformin, and if a second oral medication is needed, to select from among sodium glucose co-transporter-2 inhibitors (SGLT2s), dipeptidyl peptidase-4 (DPP-4) inhibitors, sulfonylureas, or thiazolidinediones.
The update reflects the many new medications that have received FDA approval since 2012, with SGLT2s and combinations chief among them, as well as multiple studies evaluating the safety and effectiveness of available therapies.
“Metformin, unless contraindicated, is an effective treatment strategy because it has better effectiveness, is associated with fewer adverse effects, and is cheaper than most other oral medications,” Nitin S. Damle, MD, MS, MACP, the group’s president, said in a statement. Metformin is included in several combination therapies that have received FDA approval, which allow patients to take the dual therapy in a single, daily pill.
Besides the benefits for lowering glycated hemoglobin and slowing disease progression, Damle said metformin is associated with weight loss, an added benefit given rising rates of obesity and the drug’s relatively low cost.
He addressed the issue of cost directly: “Adding a second medication to metformin may provide additional benefits,” Damle said. “However, the increased cost may not always support the added benefit, particularly for the more expensive, newer medications. ACP recommends that clinicians and patients discuss the benefits, adverse effects, and costs of additional medications.”
ACP’s guideline is important because its recommendations are likely to reach primary care physicians, who diagnose and treat the majority of patients with T2D. On its website, ACP said its members include 148,000 specialists and subspecialists in internal medicine.
The group’s call for physicians to discuss cost with patients comes as studies and reports from those in the field show patients with diabetes may not fill prescriptions for high-cost medications, or they may start and then discontinue them if the out-of-pocket costs are too high.
Diabetes affects 29 million people in the United States, with most being diagnosed with T2D. An estimated 86 million people have prediabetes. Diabetes is the seventh leading cause of death in the United States, according to CDC.
Reference
Qaseem A, Barry MJ, Humphrey LL, Forciea MA, for the Clinical Guidelines Committee of the American College of Physicians. Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline update from the American College of Physicians [published online January 3, 2017]. Ann Intern Med. doi: 10.7326/M16-1860.
How Can Employers Leverage the DPP to Improve Diabetes Rates?
February 15th 2022On this episode of Managed Care Cast, Jill Hutt, vice president of member services at the Greater Philadelphia Business Coalition on Health, explains the Coalition’s efforts to reduce diabetes rates through the Diabetes Prevention Program (DPP).
Listen
Balancing Care Access and Fragmentation for Better Outcomes in Veterans With Diabetes
April 22nd 2021The authors of a study in the April 2021 issue of The American Journal of Managed Care® discuss the possible reasons behind the link between care fragmentation and hospitalizations in veterans with diabetes, as well as potential opportunities to address disjointed care in the context of the widespread telehealth uptake seen during the COVID-19 pandemic.
Listen
What We’re Reading: ACA Perception; FDA Blood Sugar Warning; AI and Physician Burnout
February 22nd 2024More than half of US adults have a favorable view of the Affordable Care Act (ACA); smartwatches and rings that claim to measure blood sugar levels without piercing the skin could be dangerous and should be avoided; many believe artificial intelligence (AI) could be the solution to physician burnout.
Read More
Advancements in Diabetes Technology: Coverage, Challenges, and Pregnancy Considerations
February 15th 2024Expert interviews highlight advancements and challenges in diabetes care technology, including automated insulin delivery systems and continuous glucose monitors, as well as improvements in insurance coverage.
Read More